Patent ID: 9505841
Filing Date: 2016-11-29
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of enhancing the efficacy of an anticancer agent, comprising administering an anti-cancer agent and an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the anti-Ang2 antibody or the antigen-binding fragment thereof specifically binds to Ang2 and forms a complex with a Tie2 receptor via Ang2; and the anti-Ang2 antibody or an antigen-binding fragment thereof binds to Q418, P419 or a combination of Q418 and P419 in human Ang2 of SEQ ID NO: 11; or binds to 2 to 20 contiguous amino acid residues of SEQ ID NO: 11 including Q418, P419 or a combination of Q418 and P419, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises: a first heavy chain complementarity determining region (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a second heavy chain complementarity determining region (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, a third heavy chain complementarity determining region (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3, a first light chain complementarity determining region (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a second light chain complementarity determining region (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a third light chain complementarity determining region (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6.